Mineralocorticoid Receptor Antagonist Use Among Patients With Chronic Kidney Disease Who Transitioned to Dialysis.
作者信息
Tong Eric M, Zhou Hui, Pak Katherine, Huang Cheng-Wei, Broder Benjamin I, Sim John J
机构信息
Division of Nephrology, Kaiser Permanente Woodland Hills Medical Center. Woodland Hills, CA.
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA.
出版信息
Kidney Med. 2025 Feb 7;7(4):100973. doi: 10.1016/j.xkme.2025.100973. eCollection 2025 Apr.
Abstract
摘要
相似文献
1
Mineralocorticoid Receptor Antagonist Use Among Patients With Chronic Kidney Disease Who Transitioned to Dialysis.转为透析治疗的慢性肾脏病患者中盐皮质激素受体拮抗剂的使用情况
Kidney Med. 2025 Feb 7;7(4):100973. doi: 10.1016/j.xkme.2025.100973. eCollection 2025 Apr.
2
Potential target-organ protection of mineralocorticoid receptor antagonist in acute kidney disease.急性肾损伤中盐皮质激素受体拮抗剂的潜在靶器官保护作用。
J Hypertens. 2019 Jan;37(1):125-134. doi: 10.1097/HJH.0000000000001876.
3
Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis.矿物质皮质激素受体拮抗剂在透析治疗肾衰竭患者中的疗效和安全性：系统评价和荟萃分析。
Clin J Am Soc Nephrol. 2021 Jun;16(6):916-925. doi: 10.2215/CJN.15841020. Epub 2021 Jun 11.
4
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.非甾体类盐皮质激素受体拮抗剂非奈利酮可改善非糖尿病慢性肾脏病的舒张功能障碍。
J Am Heart Assoc. 2024 Jun 18;13(12):e032971. doi: 10.1161/JAHA.123.032971. Epub 2024 Jun 6.
5
Mineralocorticoid receptor antagonists in patients with chronic kidney disease.慢性肾脏病患者的盐皮质激素受体拮抗剂。
Pharmacol Ther. 2021 Mar;219:107701. doi: 10.1016/j.pharmthera.2020.107701. Epub 2020 Oct 4.
6
Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.非甾体类盐皮质激素受体拮抗剂在糖尿病肾病患者中的疗效
Postgrad Med. 2023 Apr;135(3):224-233. doi: 10.1080/00325481.2022.2060598. Epub 2022 Apr 20.
7
Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease.在慢性肾脏病的真实世界患者中，使用盐皮质激素受体拮抗剂与肾脏硬终点的相关性。
Hypertension. 2022 Mar;79(3):679-689. doi: 10.1161/HYPERTENSIONAHA.121.18360. Epub 2022 Jan 14.
8
Efficacy of Mineralocorticoid Receptor Antagonists on Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: An Umbrella Review.盐皮质激素受体拮抗剂对慢性肾脏病患者肾脏和心血管结局的疗效：一项伞状综述
Kidney Med. 2024 Dec 13;7(2):100943. doi: 10.1016/j.xkme.2024.100943. eCollection 2025 Feb.
9
Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists.糖尿病肾病中的醛固酮受体相关机制及醛固酮受体拮抗剂的临床意义。
Am J Nephrol. 2023;54(1-2):50-61. doi: 10.1159/000528783. Epub 2023 Jan 20.
10
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.矿皮质激素受体拮抗剂耐受性研究-心力衰竭（ARTS-HF）的原理和设计：在患有慢性心力衰竭恶化且伴有糖尿病和/或慢性肾脏病的患者中，比较非奈利酮与依普利酮的一项随机研究。
Eur J Heart Fail. 2015 Feb;17(2):224-32. doi: 10.1002/ejhf.218.
本文引用的文献
1
All-Cause and Cardiovascular-Related Mortality in CKD Patients With and Without Heart Failure: A Population-Based Cohort Study in Kaiser Permanente Southern California.患有和未患有心力衰竭的慢性肾脏病患者的全因死亡率和心血管相关死亡率：南加州凯撒医疗机构基于人群的队列研究
Kidney Med. 2023 Mar 9;5(5):100624. doi: 10.1016/j.xkme.2023.100624. eCollection 2023 May.
2
The effects of mineralocorticoid receptor antagonists on cardiovascular outcomes in patients with end-stage renal disease and heart failure.盐皮质激素受体拮抗剂对终末期肾病合并心力衰竭患者心血管结局的影响。
Eur J Heart Fail. 2023 Jan;25(1):98-107. doi: 10.1002/ejhf.2740. Epub 2022 Dec 11.
3
Causes of Death in End-Stage Kidney Disease: Comparison between the United States Renal Data System and a Large Integrated Health Care System.终末期肾病的死因：美国肾脏数据系统与大型综合医疗保健系统的比较
Am J Nephrol. 2022;53(1):32-40. doi: 10.1159/000520466. Epub 2022 Jan 11.
4
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.β受体阻滞剂在开始维持性透析的心力衰竭患者中的使用与死亡率的关系。
Am J Kidney Dis. 2021 May;77(5):704-712. doi: 10.1053/j.ajkd.2020.07.023. Epub 2020 Nov 15.
5
Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.在透析依赖的 ESRD 患者中螺内酯的安全性和心血管疗效（SPin-D）：一项随机、安慰剂对照、多剂量试验。
Kidney Int. 2019 Apr;95(4):973-982. doi: 10.1016/j.kint.2018.08.034. Epub 2018 Nov 23.
6
Racial and Ethnic Differences in Antihypertensive Medication Use and Blood Pressure Control Among US Adults With Hypertension: The National Health and Nutrition Examination Survey, 2003 to 2012.2003年至2012年美国高血压成年人使用抗高血压药物和血压控制情况的种族和民族差异：国家健康与营养检查调查
Circ Cardiovasc Qual Outcomes. 2017 Jan;10(1). doi: 10.1161/CIRCOUTCOMES.116.003166.
7
The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.《需透析患者应用盐皮质激素受体拮抗剂的安全性和疗效：系统评价和荟萃分析》
Am J Kidney Dis. 2016 Oct;68(4):591-598. doi: 10.1053/j.ajkd.2016.04.011. Epub 2016 Jun 3.
8
Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.螺内酯可降低血液透析患者的心血管和脑血管发病率和死亡率。
J Am Coll Cardiol. 2014 Feb 18;63(6):528-36. doi: 10.1016/j.jacc.2013.09.056. Epub 2013 Oct 30.
9
Hypokalemia in peritoneal dialysis patients.腹膜透析患者的低钾血症
Perit Dial Int. 1996 Nov-Dec;16(6):652.
Zotero 插件